Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified

Hologic

(

HOLX

) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Hologic as such a stock due to the following factors:

  • HOLX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $101.1 million.
  • HOLX is up 4.3% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in HOLX with the Ticky from Trade-Ideas. See the FREE profile for HOLX NOW at Trade-Ideas

More details on HOLX:

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States and internationally. The company operates in four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. HOLX has a PE ratio of 92. Currently there are 8 analysts that rate Hologic a buy, 1 analyst rates it a sell, and 7 rate it a hold.

The average volume for Hologic has been 2.1 million shares per day over the past 30 days. Hologic has a market cap of $10.6 billion and is part of the health care sector and health services industry. The stock has a beta of 0.97 and a short float of 6.3% with 4.43 days to cover. Shares are up 40.4% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Hologic as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

Highlights from the ratings report include:

  • HOLOGIC INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, HOLOGIC INC turned its bottom line around by earning $0.06 versus -$4.33 in the prior year. This year, the market expects an improvement in earnings ($1.60 versus $0.06).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 385.1% when compared to the same quarter one year prior, rising from -$16.77 million to $47.80 million.
  • HOLX's revenue growth trails the industry average of 26.3%. Since the same quarter one year prior, revenues slightly increased by 4.9%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The gross profit margin for HOLOGIC INC is rather high; currently it is at 66.36%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 7.29% is above that of the industry average.
  • Net operating cash flow has significantly increased by 128.53% to $157.80 million when compared to the same quarter last year. In addition, HOLOGIC INC has also vastly surpassed the industry average cash flow growth rate of -3.96%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.